Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects

[1]  Peter Bjerring,et al.  Codeine increases pain thresholds to copper vapor laser stimuli in extensive but not poor metabolizers of sparteine , 1990, Clinical pharmacology and therapeutics.

[2]  J. S. Miles,et al.  Identification of the primary gene defect at the cytochrome P450 CYP2D locus , 1990, Nature.

[3]  U. Meyer,et al.  Genotyping of poor metabolisers of debrisoquine by allele-specific PCR amplification , 1990, The Lancet.

[4]  L. Pickle,et al.  Lung cancer and the debrisoquine metabolic phenotype. , 1990, Journal of the National Cancer Institute.

[5]  Choongrak Kim,et al.  Exact Properties of Some Exact Test Statistics for Comparing Two Binomial Proportions , 1990 .

[6]  K. Brøsen,et al.  Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark. , 1989, British journal of clinical pharmacology.

[7]  M. Relling,et al.  Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin‐oxidation and N‐acetylation phenotypes in children , 1989, Clinical pharmacology and therapeutics.

[8]  U. Meyer,et al.  Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in man. , 1988, Biochemistry.

[9]  A. Llerena,et al.  Debrisoquin oxidation polymorphism in a Spanish population , 1988, Clinical pharmacology and therapeutics.

[10]  R. Skoda,et al.  Two mutant alleles of the human cytochrome P-450db1 gene (P450C2D1) associated with genetically deficient metabolism of debrisoquine and other drugs. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[11]  D. Nebert,et al.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism , 1988, Nature.

[12]  L. Bertilsson,et al.  LOW FREQUENCY OF SLOW DEBRISOQUINE HYDROXYLATION IN A NATIVE CHINESE POPULATION , 1987, The Lancet.

[13]  G. Tucker,et al.  Metoprolol and debrisoquin metabolism in nigerians: Lack of evidence for polymorphic oxidation , 1986, Clinical pharmacology and therapeutics.

[14]  S. Otton,et al.  Sparteine oxidation is practically abolished in quinidine-treated patients. , 1986, British journal of clinical pharmacology.

[15]  G. Shenfield,et al.  Debrisoquine oxidation in an Australian population. , 1986, British journal of clinical pharmacology.

[16]  J. Bircher,et al.  Polymorphic dextromethorphan metabolism: Co‐segregation of oxidative O‐demethylation with debrisoquin hydroxylation , 1985, Clinical pharmacology and therapeutics.

[17]  R. Branch,et al.  Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations , 1985, Clinical pharmacology and therapeutics.

[18]  M. Eichelbaum,et al.  Dissociation of co‐regulatory control of debrisoquin/phenformin and sparteine oxidation in Ghanaians , 1985, Clinical pharmacology and therapeutics.

[19]  G. Wilkinson,et al.  Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism , 1984, Clinical pharmacology and therapeutics.

[20]  M. Hetzel,et al.  Metabolic oxidation phenotypes as markers for susceptibility to lung cancer , 1984, Nature.

[21]  S. Devesa,et al.  Socioeconomic and racial differences in lung cancer incidence. , 1983, American journal of epidemiology.

[22]  J. Idle,et al.  The genetic control of sparteine and debrisoquine metabolism in man with new methods of analysing bimodal distributions. , 1983, Journal of medical genetics.

[23]  A. Cohen,et al.  Finite Mixture Distributions , 1982 .

[24]  J. Idle,et al.  A study of the debrisoquine hydroxylation polymorphism in a Nigerian population. , 1980, Xenobiotica; the fate of foreign compounds in biological systems.

[25]  J. Idle,et al.  A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. , 1980, Journal of medical genetics.

[26]  J. Idle,et al.  Debrisoquin hydroxylation polymorphism among Ghanaians and Caucasians , 1979, Clinical pharmacology and therapeutics.

[27]  J. Idle,et al.  POLYMORPHIC HYDROXYLATION OF DEBRISOQUINE IN MAN , 1977, The Lancet.

[28]  R. Stone,et al.  Urinary kallikrein and plasma renin activity as determinants of renal blood flow. The influence of race and dietary sodium intake. , 1977, The Journal of clinical investigation.

[29]  S. Sunahara,et al.  Genetical and Geographic Studies on Isoniazid Inactivation , 1961, Science.

[30]  O. Hinsvark,et al.  Quantitative determination of dextromethorphan and three metabolites in urine by reverse-phase high-performance liquid chromatography. , 1984, Journal of pharmaceutical sciences.